Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine

Sebastian Mondaca,Pedram Razavi,Chongrui Xu,Michael Offin,Mackenzie L. Myers,Maurizio Scaltriti,Jaclyn F. Hechtman,Mikaela Bradley,Eileen M. O’Reilly,Michael F. Berger,David B. Solit,Bob T. Li,Ghassan K. Abou-Alfa

Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine

2019

Sebastian Mondaca
Pedram Razavi
Chongrui Xu
Michael Offin
Mackenzie L. Myers
Maurizio Scaltriti
Jaclyn F. Hechtman
Mikaela Bradley
Eileen M. O’Reilly
Michael F. Berger
David B. Solit
Bob T. Li
Ghassan K. Abou-Alfa

PURPOSEBiliary tract cancers (BTCs), which include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (EHC), and gallbladder cancer (GBC), have limited treatment options. We sou...

Keywords:

Extrahepatic Cholangiocarcinoma
Ado-trastuzumab emtansine
Cancer research
Intrahepatic Cholangiocarcinoma
Medicine
Cancer
Gallbladder cancer
biliary cancer
treatment options
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations